ResultsIQ

ResultsIQ › Latest results › Divi's Laboratories Limited

Divi's Laboratories Limited Q2 FY27 earnings call summary

NSE: DIVISLAB · BSE: 532488

Earnings call of 7 Nov 2026, summarised by AI from the filing.

Net material consumption fell to about 32% of sales revenue (H1 FY26: 40%) on custom synthesis mix and Unit 3 backward integration.

Key takeaways

  1. Material cost Net material consumption fell to about 32% of sales revenue (H1 FY26: 40%) on custom synthesis mix and Unit 3 backward integration.
  2. Validation batches Validation quantities supplied for select custom synthesis projects; one of three dedicated projects is very close to commercialization.
  3. Input costs Volatility in petrochemical-based solvent prices and higher freight costs from Red Sea disruption.

Original filing on BSE

Divi's Laboratories Limited Q2 FY27 results

As filed: Revenue ₹3,676 cr (+35% year on year), EBITDA ₹1,566 cr (+76% year on year), PAT ₹1,127 cr (+64% year on year), EBITDA margin 42.6% (+989 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹3,080 cr (+28% year on year), EBITDA ₹1,255 cr (+72% year on year), PAT ₹902 cr (+66% year on year), EBITDA margin 40.8% (+1,000 bps). Score 100 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Profit rose ₹357 cr on a year ago, more than the ₹115 cr it added the year before. Share price after the results: +17.5% in 30 days (Nifty 500: 0.0%).
  • Q4 FY26: Revenue ₹2,831 cr (+10% year on year), EBITDA ₹934 cr (+5% year on year), PAT ₹751 cr (+13% year on year), EBITDA margin 33.0% (−128 bps). Score 31 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 128 bps year on year. Revenue rose ₹246 cr on a year ago, against ₹282 cr the year before. Share price after the results: −1.4% in 30 days (Nifty 500: +2.7%).
  • Q3 FY26: Revenue ₹2,604 cr (+12% year on year), EBITDA ₹890 cr (+20% year on year), PAT ₹583 cr (−1% year on year), EBITDA margin 34.2% (+214 bps). Score 28 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was well below it. EBITDA margin rose 214 bps year on year. Revenue fell 4% from last quarter. Revenue rose ₹285 cr on a year ago, against ₹464 cr the year before. Share price after the results: −1.7% in 30 days (Nifty 500: −9.9%).
  • Q2 FY26: Revenue ₹2,715 cr (+16% year on year), EBITDA ₹888 cr (+24% year on year), PAT ₹689 cr (+35% year on year), EBITDA margin 32.7% (+208 bps). Score 44 of 100, In line with trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was below it. EBITDA margin rose 208 bps year on year. Profit rose ₹179 cr on a year ago, more than the ₹162 cr it added the year before. Share price after the results: −2.7% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹2,410 cr (+14% year on year), EBITDA ₹729 cr (+17% year on year), PAT ₹545 cr (+27% year on year), EBITDA margin 30.3% (+88 bps). Score 48 of 100, In line with trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin rose 88 bps year on year. Revenue fell 7% from last quarter. Revenue rose ₹292 cr on a year ago, against ₹340 cr the year before. Share price after the results: −6.2% in 30 days (Nifty 500: +0.1%).
  • Q4 FY25: Revenue ₹2,585 cr (+12% year on year), EBITDA ₹886 cr (+21% year on year), PAT ₹662 cr (+23% year on year), EBITDA margin 34.3% (+253 bps). Score 35 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin rose 253 bps year on year. Revenue rose ₹282 cr on a year ago, against ₹352 cr the year before. Share price after the results: +6.5% in 30 days (Nifty 500: +1.0%).
  • Q3 FY25: Revenue ₹2,319 cr (+25% year on year), EBITDA ₹743 cr (+52% year on year), PAT ₹589 cr (+65% year on year), EBITDA margin 32.0% (+568 bps). Score 82 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 568 bps year on year. Profit rose ₹231 cr on a year ago, more than the ₹51.0 cr it added the year before.

Past price moves after results do not indicate future moves. Not a recommendation.

Divi's Laboratories Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.